Biopharm Business - BioPharm International

ADVERTISEMENT

Biopharm Business
Insight and analysis to business aspects of biopharmaceutical development. Mergers, acquisitions, legal activities.

A 25-Year Retrospective on Bio-Engineering

July 1, 2012

Steven S. Kuwahara, PhD, principal consultant at GXP BioTechnology LLC, gives an update on "Engineering the Cell-System Interface."

Pharmaceutical Dealmaking Broadens its Partnering Base

July 1, 2012

Collaborative R&D models coincide with new ways to fund translational research.

Using a Systematic Approach to Select Critical Process Parameters

July 1, 2012

Harmonized regulations call for a risk-based and systematic approach to evaluating and selecting CPPs.

Developing Discoveries into New Therapeutics

June 1, 2012

Formulators and developers are at the heart of the industry's basic premise—they are saving lives.

Reducing Human Error

June 1, 2012

Leading industry collaborators outline top 10 best practices for human error reduction.

Developing Alternatives to ELISA-Based Biomarker Assays

June 1, 2012

The authors discuss a new, rapid immunoassay for the detection of biomarkers.

25 Years of Biopharmaceutical Innovation: An Expert Roundtable

June 1, 2012

Industry experts discuss significant achievements. Plus: What's in store for the future.

Creating a Product Portfolio from the Ground Up

June 1, 2012

Mike Clayman, CEO of Flexion Therapeutics, talks about his company's strategy to focus on a single therapeutic area.

Interview with FDA: Adopting New Strategies to Oversee Global Economy

June 1, 2012

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.

ADVERTISEMENT

ADVERTISEMENT

Click here